Matches in Nanopublications for { ?s ?p "[In summary, KRAS G12C mutations, TTF-1, and napsin A were associated with primary lung adenocarcinoma, whereas KRAS G12R mutations, CK20, and CDX2 favored pancreatic adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- NP308813.RAQKo3CPXbUjNlWfhfGE6l21HTXinlCfsGj4vsG4yuDtU130_assertion description "[In summary, KRAS G12C mutations, TTF-1, and napsin A were associated with primary lung adenocarcinoma, whereas KRAS G12R mutations, CK20, and CDX2 favored pancreatic adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308813.RAQKo3CPXbUjNlWfhfGE6l21HTXinlCfsGj4vsG4yuDtU130_provenance.
- NP824624.RAahz-qpt7EJZjY0TMY3shhPFd5bvIeVfhudL0nw_68mc130_assertion description "[In summary, KRAS G12C mutations, TTF-1, and napsin A were associated with primary lung adenocarcinoma, whereas KRAS G12R mutations, CK20, and CDX2 favored pancreatic adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP824624.RAahz-qpt7EJZjY0TMY3shhPFd5bvIeVfhudL0nw_68mc130_provenance.
- assertion description "[In summary, KRAS G12C mutations, TTF-1, and napsin A were associated with primary lung adenocarcinoma, whereas KRAS G12R mutations, CK20, and CDX2 favored pancreatic adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In summary, KRAS G12C mutations, TTF-1, and napsin A were associated with primary lung adenocarcinoma, whereas KRAS G12R mutations, CK20, and CDX2 favored pancreatic adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1096861.RAZSlVpVAfSQ_xrDTZvX6PzPIBi4SFDOOv13rkMLq6frQ130_assertion description "[In summary, KRAS G12C mutations, TTF-1, and napsin A were associated with primary lung adenocarcinoma, whereas KRAS G12R mutations, CK20, and CDX2 favored pancreatic adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1096861.RAZSlVpVAfSQ_xrDTZvX6PzPIBi4SFDOOv13rkMLq6frQ130_provenance.
- assertion description "[In summary, KRAS G12C mutations, TTF-1, and napsin A were associated with primary lung adenocarcinoma, whereas KRAS G12R mutations, CK20, and CDX2 favored pancreatic adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In summary, KRAS G12C mutations, TTF-1, and napsin A were associated with primary lung adenocarcinoma, whereas KRAS G12R mutations, CK20, and CDX2 favored pancreatic adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP824620.RAtiO5Ob_SyIWnBfmD2gChYCnRouYc6iXTN9jtPwN1uzo130_assertion description "[In summary, KRAS G12C mutations, TTF-1, and napsin A were associated with primary lung adenocarcinoma, whereas KRAS G12R mutations, CK20, and CDX2 favored pancreatic adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP824620.RAtiO5Ob_SyIWnBfmD2gChYCnRouYc6iXTN9jtPwN1uzo130_provenance.
- NP1096855.RAHUts3k7Dh79cOSrvpWiKx6HaBXfGzH0P5HJRuxGbavY130_assertion description "[In summary, KRAS G12C mutations, TTF-1, and napsin A were associated with primary lung adenocarcinoma, whereas KRAS G12R mutations, CK20, and CDX2 favored pancreatic adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1096855.RAHUts3k7Dh79cOSrvpWiKx6HaBXfGzH0P5HJRuxGbavY130_provenance.
- NP1096859.RAgjDMsvi7DwkqudfLE7hE_J9JBRlmvcXQtQFrTSrj5oA130_assertion description "[In summary, KRAS G12C mutations, TTF-1, and napsin A were associated with primary lung adenocarcinoma, whereas KRAS G12R mutations, CK20, and CDX2 favored pancreatic adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1096859.RAgjDMsvi7DwkqudfLE7hE_J9JBRlmvcXQtQFrTSrj5oA130_provenance.